Trastuzumab
-
Trastuzumab
structure -
-
CAS No:
180288-69-1
-
Formula:
C10H14N6O5
-
Chemical Name:
Trastuzumab
-
Synonyms:
Herceptin;TrastuzuMab(Herceptin);TRASTUZUMAB 98 % +;IMMunoglobulin G1,anti-(huMan p185neu receptor) (huMan-Mouse Monoclonal rhuMab HER2 g1-chain), disulfide with huMan-MouseMonoclonal rhuMab HER2 light chain, diMer;TRASTUZUMAB 95 % +;Anti HER2, Ig gamma-1 chain C region;Recombinant humanized anti-HER2 antibody;RhuMab HER2
- Categories:
-
CAS No:
Description
Trastuzumab, marketed as Herceptin, is a humanized monoclonal antibody whose history is a paradigm of breakthroughs in targeted therapy in oncology. Its development involves a close integration of basic scientific discoveries, clinical validation, and drug engineering. The story begins in the mid-1980s when Axel Ullrich, in his research team at Genentech, successfully cloned the HER2 (human epidermal growth factor receptor 2) gene, revealing its role in cell growth and proliferation. Subsequently, research by Dennis J. Slamon at UCLA showed that the HER2 gene was amplified and overexpressed in approximately 25% to 30% of breast cancer patients, and this overexpression was significantly associated with disease aggressiveness, high recurrence rates, and poor prognosis. This discovery provided a clear molecular target for targeted therapy. Subsequently, Genentech scientists, particularly H. Michael Shepard and colleagues, developed a monoclonal antibody that specifically binds to and blocks the activity of the HER2 receptor based on this target. Through drug engineering optimization, trastuzumab was finally developed, which can effectively inhibit the growth of HER2-overexpressing tumor cells. After years of clinical trials, trastuzumab was approved by the U.S. Food and Drug Administration (FDA) on September 25, 1998, for the treatment of HER2-positive metastatic breast cancer.
Herceptin (generic name: trastuzumab) is not a chemo drug, it is a targeted therapy anticancer drug.Herceptin contains one active ingredient, trastuzumab, and is given as an intravenous (IV) infusion slowly into a vein. Herceptin Hylecta contains two active ingredients, trastuzumab and hyaluronidase-oysk, and is given as a subcutaneous injection, which is an injection that goes under the skin.
Trastuzumab Use and Manufacturing
Trastuzumab is used to treat breast cancer. It is effective against tumors that overexpress the HER2/neu protien. As part of chemotherapy regimen for adjuvant treatment of lymph-node positive, HER2/neu positive cancer.
Drug Function and Efficacy
It inhibits the proliferation of HER2-overexpressing tumor cells and induces antibody-dependent cell-mediated cytotoxicity (ADCC), which is preferentially produced in HER2-overexpressing cancer cells than in HER2-non-overexpressing cancer cells.
Recommended Suppliers of Trastuzumab
-
![China]()
CN
3 YRS
Business licensedTrader Supplier of Apigenin,PQQ,NMNHInquiryUnit Price: $10.1-11.11 /G FOBCAS No.: 180288-69-1Grade: Chemical GradeContent: 99% -
InquiryCAS No.: 180288-69-1Grade: Industrial GradeContent: 99%
-
![China]()
CN
1 YR
Business licensedTrader Supplier of API,Pembrolizumab,semaglutide -
![China]()
CN
1 YR
Business licensedTrader Supplier of Antibody,Recombinant Protein,ELISA Kit -
![China]()
CN
1 YR
Business licensedTrader Supplier of Peptides,API,Intermediate
Learn More Other Chemicals
-
[3,4-diacetyloxy-5-(4-amino-2-oxo-1,3,5-triazin-1-yl)oxolan-2-yl]methyl acetate
10302-78-0
-
Atomoxetine Related Compound C (10 mg) (N-methyl-3-phenyl-3-(p-tolyloxy)propan-1-amine hydrochloride)
873310-31-7
-
(3S)-4-Chloro-1,3-butanediol
139013-68-6
-
5-chloro-N-(4-nitrophenyl)pentanamide Formula
1039914-85-6
-
6-AMino-5-azacytidine Formula
105331-00-8
-
Amoxicillin Related Compound D (50 mg) ((4S)-2-{[(R)-2-amino-2-(4-hydroxyphenyl)acetamido](carboxy)methyl}-5,5-dimethylthiazolidine-4-carboxylic acid, monosodium salt) Formula
68728-47-2
-
4-AMINO-6-METHYL-1,3,5-TRIAZIN-2-OL Structure
16352-06-0
-
Littorine Structure
21956-47-8
-
What is 10βH-Guai-11(13)-en-12-oic acid,3α,4:10,14-diepoxy-2β,5,6α,8β-tetrahydroxy-,12,6-lactone,8-(2-methylcrotonate),(Z)-
20071-54-9
-
What is 2-(R)-[1-(S)-(3,5-Bis(trifluoromethyl)phenyl)ethoxy]-3-(S)-fluorophenylmorpholine
170729-79-0